Dummy run and conformity indices in the ongoing EORTC low-grade glioma trial 22033-26033: First evaluation of quality of radiotherapy planning.

PURPOSE Early assessment of radiotherapy (RT) quality in the ongoing EORTC trial comparing primary temozolomide versus RT in low-grade gliomas. MATERIALS AND METHODS RT plans provided for dummy cases were evaluated and compared against expert plans. We analysed: (1) tumour and organs-at-risk delineation, (2) geometric and dosimetric characteristics, (3) planning parameters, compliance with dose prescription and Dmax for OAR (4) indices: RTOG conformity index (CI), coverage factor (CF), tissue protection factor (PF); conformity number (CN = PF x CF); dose homogeneity in PTV (U). RESULTS Forty-one RT plans were evaluated. Only two (5%) centres were requested to repeat CTV-PTV delineations. Three (7%) plans had a significant under-dosage and dose homogeneity in one deviated > 10%. Dose distribution was good with mean values of 1.5, 1, 0.68, and 0.68 (ideal values = 1) for CI, CF, PF, and CN, respectively. CI and CN strongly correlated with PF and they correlated with PTV. Planning with more beams seems to increase PTV(Dmin), improving CF. U correlated with PTV(Dmax). CONCLUSION Preliminary results of the dummy run procedure indicate that most centres conformed to protocol requirements. To quantify plan quality we recommend systematic calculation of U and either CI or CN, both of which measure the amount of irradiated normal brain tissue.

[1]  Stefan G Scheib,et al.  Quantifying the degree of conformity in radiosurgery treatment planning. , 2003, International journal of radiation oncology, biology, physics.

[2]  R. Garcia,et al.  Evaluation dosimétrique d'une radiothérapie conformationnelle: le facteur de conformation , 2000 .

[3]  A Brahme,et al.  Individualizing cancer treatment: biological optimization models in treatment planning and delivery. , 2001, International journal of radiation oncology, biology, physics.

[4]  Jean-Yves Giraud,et al.  Quality assurance of the EORTC trial 22911. A phase III study of post-operative external radiotherapy in pathological stage T3N0 prostatic carcinoma: the dummy run. , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[5]  Philippe Cornu,et al.  Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis. , 2002, International journal of radiation oncology, biology, physics.

[6]  Icru Prescribing, recording, and reporting photon beam therapy , 1993 .

[7]  Barbara Fisher,et al.  Quality assurance of the EORTC 26981/22981; NCIC CE3 intergroup trial on radiotherapy with or without temozolomide for newly-diagnosed glioblastoma multiforme: the individual case review. , 2004, European journal of cancer.

[8]  J. Horiot,et al.  Quality assurance control in the EORTC cooperative group ofradiotherapy , 1986 .

[9]  M. Moerland,et al.  A conformation number to quantify the degree of conformality in brachytherapy and external beam irradiation: application to the prostate. , 1997, International journal of radiation oncology, biology, physics.

[10]  Søren M Bentzen,et al.  Radiation therapy: intensity modulated, image guided, biologically optimized and evidence based. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[11]  Myonggeun Yoon,et al.  A new homogeneity index based on statistical analysis of the dose–volume histogram , 2007, Journal of applied clinical medical physics.

[12]  S. Bentzen Towards evidence based radiation oncology: improving the design, analysis, and reporting of clinical outcome studies in radiotherapy. , 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[13]  Steve B Jiang,et al.  On dose distribution comparison. , 2006, Physics in medicine and biology.

[14]  J. Horiot,et al.  Quality assurance control in the EORTC cooperative group of radiotherapy. 1. Assessment of radiotherapy staff and equipment. European Organization for Research and Treatment of Cancer. , 1986, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[15]  J. Sham,et al.  Target dose conformity in 3-dimensional conformal radiotherapy and intensity modulated radiotherapy. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[16]  W. De Gersem,et al.  Radiotherapy of prostate cancer with or without intensity modulated beams: a planning comparison. , 2000, International journal of radiation oncology, biology, physics.

[17]  Georges Noël,et al.  Conformity index: a review. , 2006, International journal of radiation oncology, biology, physics.

[18]  L. Collette,et al.  Profile of European radiotherapy departments contributing to the EORTC Radiation Oncology Group (ROG) in the 21st century. , 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[19]  A. Karim,et al.  A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. , 1996, International journal of radiation oncology, biology, physics.

[20]  Jean-Yves Giraud,et al.  Quality assurance in the 22991 EORTC ROG trial in localized prostate cancer: dummy run and individual case review. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[21]  T Knöös,et al.  Volumetric and dosimetric evaluation of radiation treatment plans: radiation conformity index. , 1998, International journal of radiation oncology, biology, physics.

[22]  B. Scheithauer,et al.  Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  A. Cianciulli,et al.  Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.